联合检测胸液端粒酶和细胞角蛋白19片段对肺癌胸腔积液的诊断价值

目的 探讨联合检测肿瘤标记物端粒酶和细胞角质蛋白19片段（CYFRA21-1）对肺癌胸腔积液的诊断价值。方法 采用聚合酶链反应-酶联免疫吸附分析法（PCR-ELISA）检测胸液端粒酶活性和免疫放射分析法测定胸液CYFRA21-1水平，共检测了36例肺癌胸腔积液和33例非恶性胸腔积液，结果 肺癌胸腔积液组的胸液端粒酶和CYFRA21-1的阳性率分别为77.8%和72.2%。非恶性胸腔积液的端粒酶和CYFRA21-1的假阳性率分别为6.1%和9.1%。结论 检测胸液端粒酶和CYFRA21-1对肺癌胸腔积液的诊断均有一定的价值，联合检测综合诊断更能提高诊断准确率。

The diagnostic evaluation of telomerase assay combined with CYFRA21-1 in pleural effusion of lung cancer

Objective To explore the diagnostic evaluation of telomerase assay combined with CYFRA21 1 in pleural effusion of lung cancer.Methods Telomerase activity and CYFRA21 1 from pleural effusion of 31 lung cancer cases and 33 non malignant pleural effusion cases were detected by PCR ELISA and IRA.Results The positive rates of telomerase and CYFRE21 1 in the pleural effusion of lung cancer patients were 77.8% and 72.2%,respectively.The false positive rates of telomerase and CYFRE21 1 in the non malignant pleural effusion were 6.1% and 9.1%,respectively.Conclusion The assay of telomerase and CYFRA21 1 of pleural fluid is valuable to the diagnosis of pleural effusion of lung cancer.The combination of the two assays can increase the accuracy of the diagnosis.